AstraZeneca PLC (LON:AZN)

Market Cap	181.54B
Revenue (ttm)	43.19B
Net Income (ttm)	5.62B
Shares Out	1.55B
EPS (ttm)	3.59
PE Ratio	32.57
Forward PE	16.47
Dividend	2.45 (2.12%)
Ex-Dividend Date	Feb 20, 2025

Volume	1,330,782
Average Volume	3,102,279
Open	11,480
Previous Close	11,590
Day's Range	11,534 - 11,778
52-Week Range	9,670 - 13,388
Beta	0.20
RSI	63.81
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: London Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD